21 results
8-K
EX-99.2
LBPH
Longboard Pharmaceuticals, Inc.
1 Aug 24
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
4:10pm
devastating 3 Longboard Pharmaceuticals Differentiated & innovative clinical approaches Relevant M&A analogs JAZZ - GW $7.2B PFE - ARNA $6.7B UCB - ZGNX $1.9B
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals, Inc.
1 Jul 24
Regulation FD Disclosure
9:15am
innovative approach to potentially treating a broad range of DEE patients,” stated Dr. Randall Kaye, Longboard’s Chief Medical Officer. “The FDA
PRE 14A
LBPH
Longboard Pharmaceuticals, Inc.
28 Mar 24
Preliminary proxy
4:36pm
to 2002, and 2004 to 2006. Mr. Lind served on the board of Ceek Women’s Health, a private medical device company focused on creating innovative products … and advocated for innovative, high-quality and affordable healthcare. Dr. Le Goff held various positions within the Roche Group, a multinational
8-K
EX-99.2
y4lra39c
12 Mar 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
4:10pm
424B5
ik6hs7vk
4 Jan 24
Prospectus supplement for primary offering
4:48pm
424B5
pe5899akfgv
2 Jan 24
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
tgl0ecf1
2 Jan 24
Regulation FD Disclosure
9:44am
8-K
zves8
2 Jan 24
Regulation FD Disclosure
9:44am
8-K
EX-99.1
yj3tx4nko2hu b0d7f
29 Nov 23
Regulation FD Disclosure
8:35am
8-K
EX-99.1
69i0k7kouexar18zm4
11 Oct 23
Regulation FD Disclosure
9:26am
8-K
EX-99.1
moy5fjb2raktz29
23 Aug 23
Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study
8:46am
DEF 14A
5ynaxh3hkwyzed
13 Apr 22
Definitive proxy
4:15pm
10-K
cl63a0q xg8ykwb6
3 Mar 22
Annual report
4:31pm
424B4
1b1ew r8s6
12 Mar 21
Prospectus supplement with pricing info
5:02pm
S-1/A
vjrf0y5mu
8 Mar 21
IPO registration (amended)
6:13am
S-1
4swga8q803h mg7io
19 Feb 21
IPO registration
5:30pm
DRS/A
puvu4zc
29 Jan 21
Draft registration statement (amended)
12:00am